Kumamoto City's pharmaceutical company KM Biologics will start clinical trials within the year to enable the new coronavirus vaccine currently under development to be used in the so-called "booster inoculation", which is the third inoculation, and will be put into practical use during the next fiscal year. Clarified the idea of aiming for conversion.
This was revealed at a press conference on the 25th by Toshiaki Nagasato, president of KM Biologics, a pharmaceutical company in Kumamoto City.
According to the report, as a result of conducting initial clinical trials of the new corona vaccine currently under development from March, it was confirmed that it is as safe as the vaccines made by Pfizer and Moderna.
On top of that, clinical trials will be started within the year so that people who have already completed two vaccinations can use it in the so-called "booster vaccination" where the third vaccination is given, and if the efficacy and safety are confirmed. , Applying for approval from the government and aiming for practical use within the next fiscal year.
Regarding conducting clinical trials with booster inoculation, KM Biologics has determined that there is a high need for people who have already been inoculated twice, with nearly 70% of the total.
Regarding this vaccine, clinical trials for those who receive the first vaccination have started on 2000 people in Japan from 22nd of this month, and we are aiming for practical application within the next fiscal year.